Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding No renal reduction is specified at eGFR 15-89 mL/min/1.73 m2. Use is not recommended below 15. Limits and monitoring This applies to the olanzapine/samidorphan combination. Review opioid-related contraindications separately. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Feb 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The combination's renal section retains usual doses in mild and moderate impairment. Its moderate band starts at CrCl 30, while its severe evidence-gap statement includes 30. Limits and monitoring At exactly 30 mL/min, verify the intended regimen before use. Assess volume status and electrolytes. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 1, posted Apr 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding Omeprazole disposition in chronic impairment with CrCl 10-62 mL/min/1.73 m2 was similar to controls, with slightly higher bioavailability. Limits and monitoring Confirm the prescribed delayed-release formulation. No dialysis regimen follows from this study. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 8, posted Mar 19, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding Use the usual osimertinib dose at Cockcroft-Gault CrCl 15-89 mL/min. Below 15 mL/min no dose has been established. Limits and monitoring Confirm the renal estimate and consult the product label for the regimen and toxicity changes. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 37, posted Sep 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For adult CrCl below 30 mL/min, start immediate-release oxcarbazepine at 300 mg per day in two divided doses. Titrate slowly to response. Limits and monitoring This is half the usual adult starting dose. Confirm the preparation and monitor tolerability and serum sodium when indicated. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 40, posted Oct 30, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl below 60 mL/min, oxycodone plasma concentrations were about 50% higher than in patients with normal function. Limits and monitoring Use conservative initiation and titration with monitoring for sedation and respiratory depression. Verify the extended-release tablet. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 44, posted Jun 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The product's pharmacokinetic analysis found no clinically significant effect at CrCl 30-89 mL/min. Limits and monitoring The result does not establish a dose or timing for dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 161, posted Jun 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Severe renal impairment had little effect on measured pantoprazole pharmacokinetics compared with controls. Limits and monitoring The cited label concerns the oral product. Verify route and indication. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 1, posted Jun 22, 2011 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Bowel preparation in renal impairment warrants caution. Maintain adequate hydration and consider checking electrolytes, creatinine and BUN before and after the preparation. Limits and monitoring Review diuretics, renin-angiotensin system inhibitors and NSAIDs as potential contributors to renal risk. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Oct 12, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Use the usual pertuzumab dose at CrCl 30-90 mL/min. Data are inadequate to recommend a regimen below 30 mL/min. Limits and monitoring Verify that the order is for the intravenous pertuzumab product. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 27, posted May 04, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The product's pharmacokinetic analysis found no clinically significant effect at CrCl 30-89 mL/min. Limits and monitoring The result does not establish a dose or timing for dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Aug 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding Avoid IV posaconazole when eGFR is below 50 mL/min/1.73 m2 unless the anticipated benefit outweighs the risk of vehicle accumulation. Follow serum creatinine closely. Limits and monitoring Oral products have different formulation-specific instructions. If creatinine rises, assess switching to an appropriate oral formulation. Review 1 product or source caution
Vehicle accumulation is specific to the IV formulation. Do not apply this threshold to oral products.
DailyMed SPL version 56, posted Mar 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
